Not for publication, distribution or transmission in the United States of America, Canada, Australia or Japan
Essen, Germany. Today, Evonik Industries AG successfully placed a senior bond with a nominal value of €500 million. The proceeds of this issue will be used to partially refinance the outstanding €650 million senior bond due in March 2021. The coupon was fixed at 0.625 percent p.a. with a tenor of 5 years and 4 months.
“The bond market is an important and attractive source for Evonik’s corporate financing,” said Ute Wolf, chief financial officer of Evonik. “We use the good environment to further strengthen our liquidity position.”
The bond will be rated in line with the ratings of Evonik Industries AG which are Baa1 (negative outlook) from Moody’s and BBB+ (stable outlook) from S&P.
Joint bookrunners were Commerzbank, Goldman Sachs International, Helaba, J.P. Morgan and Société Générale. The bond was placed with around 130 domestic and international institutional investors.
The bond was placed in connection with the base prospectus dated 17 April 2020, as supplemented by a supplement dated 7 May 2020, relating to the EUR 5,000,000,000 debt issuance programme of Evonik Industries AG.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, today and tomorrow.
This publication constitutes neither an offer to sell nor a solicitation of an offer to buy securities. In particular, this document constitutes neither an offer to sell nor a solicitation of an offer to purchase securities in the United States. The securities of Evonik Industries AG described above (the "Securities") may not be offered or sold in the United States or to or for the account or benefit of "U.S. persons" (as such term is defined in Regulation S under the U. S. Securities Act of 1933, as amended (the "Securities Act")) absent registration or an exemption from registration under the Securities Act. The Securities have not been and will not be registered under the Securities Act or the securities laws of any State of the United States. There will be no public offering of the Securities in the United States.
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.